Poikiloderma is a skin condition defined by three simultaneous changes: patches of uneven pigmentation (both lighter and darker than your normal skin tone), visible tiny blood vessels near the surface, and thinning of the skin itself. These changes combine to create mottled, reddish-to-brown patches that most often appear on the neck, upper chest, and face. Poikiloderma isn’t a single disease but rather a pattern of skin damage that can result from chronic sun exposure, genetic conditions, or autoimmune disorders.
The Three Features That Define It
What makes poikiloderma distinct from a sunburn, age spot, or simple redness is that all three of its hallmark features appear together in the same area of skin. The first is irregular pigmentation: patches where your skin has become darker sit right next to patches where it has lost color, giving the area a speckled or net-like look. The second is telangiectasia, which just means the tiny blood vessels in your skin have widened and become visible, adding a reddish or purplish tone. The third is skin atrophy, where the skin has become noticeably thinner and more fragile, sometimes with a slightly papery texture.
Under a microscope, these changes are unmistakable. Biopsies of poikiloderma consistently show a flattened, thinned outer layer of skin (found in over 80% of samples in one study) along with dilated blood vessels in 96% of cases and damaged connective tissue from sun exposure in 100% of cases. That connective tissue damage, called solar elastosis, is strong evidence that ultraviolet radiation drives much of the process.
Poikiloderma of Civatte: The Most Common Form
By far the most frequently diagnosed type is poikiloderma of Civatte, named after the French dermatologist who first described it. This form develops gradually over years of cumulative sun exposure and is most common in fair-skinned, middle-aged, and older adults. It typically appears on the sides of the neck, the V-shaped area of the upper chest, the cheeks, and sometimes the forearms.
One of its telltale signs is that it spares the area directly under the chin. Because that patch of skin is naturally shaded from sunlight by the jaw, it stays unaffected while the exposed skin on either side shows the characteristic mottled reddish-brown discoloration. In a cohort study of patients with this condition, the V-shaped chest area was the most common location (96% of cases), followed by the sides of the neck (39%) and the outer face (29%).
Long-term UV exposure is the primary driver, but it isn’t the only factor. Perfumes and certain cosmetics applied to the neck and chest can react with sunlight, causing a type of chemical photosensitivity that accelerates the damage. Hormonal changes during menopause and the natural aging process also appear to play a role, though the exact mechanism isn’t fully understood.
When Poikiloderma Signals Something Deeper
Poikiloderma sometimes appears as a symptom of a more serious underlying condition rather than as a standalone problem. Two categories matter here: autoimmune diseases and genetic syndromes.
In dermatomyositis, an autoimmune disorder that causes muscle inflammation and skin changes, poikiloderma can be one of several skin manifestations alongside a distinctive purplish rash on the eyelids, raised bumps over the knuckles, and nail changes. In some cases, poikiloderma is the first visible sign before muscle weakness develops. A case report documented a patient initially diagnosed based on skin findings alone who went on to develop full muscle and laboratory features of the disease six months later.
Poikiloderma can also appear in mycosis fungoides, the most common type of cutaneous lymphoma (a cancer of the immune cells in the skin). In this context, the poikiloderma pattern tends to be more widespread, covering areas that aren’t typically sun-exposed, which helps distinguish it from the sun-driven form.
Inherited Forms and Cancer Risk
A rare but important category is congenital poikiloderma, where the skin changes are present from early childhood due to a genetic mutation. The best-known example is Rothmund-Thomson syndrome, caused by mutations in the RECQL4 gene. Both parents must carry a copy of the mutated gene for a child to be affected, and even then there’s only a 25% chance with each pregnancy.
Children with Rothmund-Thomson syndrome develop a characteristic facial rash in infancy, along with sparse hair, eyebrows, and eyelashes. Short stature, bone and dental abnormalities, cataracts, and premature aging are also common. The most serious concern is an elevated cancer risk: roughly 30% of affected individuals develop bone cancer (osteosarcoma), and about 5% develop skin cancer, most commonly squamous cell carcinoma. Other cancers, including lymphomas and leukemias, have been reported less frequently. People with this syndrome need ongoing cancer surveillance and careful sun protection, since UV exposure further raises their skin cancer risk.
Poikiloderma of Civatte, by contrast, is not considered precancerous. It reflects cumulative skin damage but does not itself progress to malignancy.
How It’s Diagnosed
Dermatologists often diagnose poikiloderma based on its visual appearance alone, particularly the Civatte form. The combination of mottled pigmentation, visible blood vessels, and skin thinning in a sun-exposed distribution with sparing under the chin is highly characteristic. A skin biopsy may be performed when the diagnosis is uncertain or when the pattern raises concern for an underlying condition like mycosis fungoides or dermatomyositis. In those cases, the biopsy helps rule out more serious possibilities.
Treatment Options and What to Expect
Managing poikiloderma of Civatte is genuinely challenging, and results can be modest. No treatment fully reverses it. The foundation of any approach is strict sun protection: daily broad-spectrum sunscreen of SPF 50 or higher, protective clothing, and avoiding direct sun during peak hours. You should also stop applying perfumes, colognes, or fragranced products to or near the affected skin.
Several topical treatments can gradually reduce the pigmentation component. Hydroquinone-based creams help fade darker patches. Retinoids (vitamin A derivatives) can improve skin texture and pigmentation when used consistently for about a year. Alpha hydroxy acids also help reduce brown discoloration. A mild steroid cream applied twice daily for two to four months can calm any inflammatory component, though this is a short-term measure.
For the redness and visible blood vessels, light-based treatments are the most effective option. Pulsed dye lasers and intense pulsed light (IPL) devices target the dilated blood vessels and excess pigment directly. In a study using a newer pulsed dye laser with a larger treatment spot, 59% of patients achieved greater than 50% improvement, with an average improvement of 49% across all participants. KTP lasers and fractionated lasers (both ablative and non-ablative) have also shown success. One caution: higher-energy laser settings have caused lasting loss of skin color in some patients, so treatment requires careful calibration by an experienced provider.
These laser treatments typically require multiple sessions spaced weeks apart, and the improvements are gradual. Even with good results, continued sun protection is essential to prevent the condition from progressing again.